2 versions

CosmeticWhat changed in REPORTED TO SENATEcompared with INTRODUCED IN SENATE (Feb 11, 2025)

Technical corrections only. The diff between v1 and v2 primarily reflects procedural updates, including the addition of co-sponsors, the bill being reported by committee, and the assignment of a calendar number. No substantive policy changes were made to the bill's text.

S. 527119th CongressIntroduced Feb 11, 2025

Prescription Pricing for the People Act of 2025

Reported To SenateCommerceSubstantive

View bill text

Sponsor: Sen. Grassley, Chuck [R-IA]
Committees: Judiciary Committee (primary)
Last action: Apr 10, 2025

Bottom line

The 'Prescription Pricing for the People Act of 2025' directs the FTC to study pharmaceutical supply chain intermediaries, identify anticompetitive practices, and recommend legislative solutions to Congress.

What it actually does

This bill mandates the Federal Trade Commission (FTC) to conduct a comprehensive study on the role of intermediaries, such as pharmacy benefit managers (PBMs) and pharmacy services administrative organizations (PSAOs), in the pharmaceutical supply chain. The study must investigate specific practices like price discrepancies, patient steering, data usage, and formulary designs. The FTC is then required to report its findings and provide policy and legislative recommendations to Congress to improve transparency, competition, and ensure consumers benefit from market efficiencies.

Proponents argue

Supporters argue that this bill is essential for shedding light on the opaque practices of pharmacy benefit managers and other intermediaries that may be driving up prescription drug costs for consumers and payers. They contend that a thorough FTC study, focusing on specific areas like price discrepancies and patient steering, is necessary to expose potential anticompetitive behaviors and inform effective policy solutions to foster greater competition and lower drug prices.

Opponents contend

Potential opponents, such as PBMs and their industry associations, might argue that the bill's mandated study is duplicative of existing market analyses or that PBMs already provide significant value by negotiating discounts and managing drug benefits, thereby reducing overall costs. They could contend that increased regulation or transparency requirements might disrupt efficient market operations, reveal proprietary business strategies, or ultimately harm consumers by limiting PBMs' ability to secure favorable terms.

The bill is short and clearly written, making it highly accessible for a quick and comprehensive understanding.

Section 1

Short Title

prominently featuredstraightforward

This section establishes the official popular name of the Act as the 'Prescription Pricing for the People Act of 2025'. This title provides a concise and recognizable name for the legislation, making it easier to reference and discuss in public and legislative discourse.

GroupImpactMechanismScale

GroupGeneral PublicImpactProvides a clear and memorable name for the legislation.MechanismScale

Supporters argue

Proponents argue that a clear and descriptive short title helps communicate the bill's purpose to the public and facilitates legislative tracking and discussion.

Critics contend

No specific opposition is typically raised against the short title of a bill, as it is a standard legislative practice.

Tradeoffs

None inherent in the short title itself.

Section 3(a)

FTC Study of Pharmaceutical Supply Chain Intermediaries

prominently featuredmoderately complex

This provision mandates the Federal Trade Commission (FTC) to conduct a detailed study and submit a report to Congress within one year of the bill's enactment. The study must specifically examine whether pharmacy benefit managers (PBMs) engage in practices such as charging payers more than they reimburse pharmacies, steering patients to PBM-owned pharmacies, using proprietary data from independent pharmacies for competitive advantage, or designing formularies to favor higher-cost drugs. It also requires the FTC to analyze competition trends, how companies assess intermediaries, and any legal or regulatory obstacles the FTC faces in enforcing antitrust laws in this sector.

Section 3(a)(2)(C)

Policy and Legislative Recommendations

prominently featuredstraightforward

As a key component of its final report, the FTC is required to provide specific policy or legislative recommendations to Congress. These recommendations are intended to improve transparency and competition within the pharmaceutical supply chain, prevent and deter anticompetitive behavior, and ensure that consumers ultimately benefit from any cost savings or efficiencies that may arise from mergers and consolidations in the industry.

Section 4

Report on Sole-Source Drug Manufacturers

mentioned in summarymoderately complex

This section requires the FTC to submit a separate report to Congress specifically focusing on manufacturers of sole-source drugs. The report must detail the number and nature of complaints received by the FTC concerning alleged anticompetitive conduct by these manufacturers. It also requires an assessment of the FTC's current ability to bring enforcement actions against such manufacturers and includes policy or legislative recommendations to strengthen enforcement actions related to anticompetitive behavior in this specific market segment.

About this analysis. AI-Generated from the official bill text and available committee reports. Gaps in available data are noted explicitly. Verify important details with the official Congress.gov record.

CosmeticWhat changed in REPORTED TO SENATEcompared with INTRODUCED IN SENATE (Feb 11, 2025)

S. 527119th CongressIntroduced Feb 11, 2025

Prescription Pricing for the People Act of 2025

Reported To SenateCommerceSubstantive

View bill text

Sponsor: Sen. Grassley, Chuck [R-IA]
Committees: Judiciary Committee (primary)
Last action: Apr 10, 2025

Bottom line

What it actually does

Proponents argue

Opponents contend

The bill is short and clearly written, making it highly accessible for a quick and comprehensive understanding.

Section 1

Short Title

prominently featuredstraightforward

GroupImpactMechanismScale

GroupGeneral PublicImpactProvides a clear and memorable name for the legislation.MechanismScale

Supporters argue

Proponents argue that a clear and descriptive short title helps communicate the bill's purpose to the public and facilitates legislative tracking and discussion.

Critics contend

No specific opposition is typically raised against the short title of a bill, as it is a standard legislative practice.

Tradeoffs

None inherent in the short title itself.

Section 3(a)

FTC Study of Pharmaceutical Supply Chain Intermediaries

prominently featuredmoderately complex

Section 3(a)(2)(C)

Policy and Legislative Recommendations

prominently featuredstraightforward

Section 4

Report on Sole-Source Drug Manufacturers

mentioned in summarymoderately complex